Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News SCYNEXIS Inc SCYX

Healthcare
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens,... see more

Recent & Breaking News (NDAQ:SCYX)

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 6, 2024

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

GlobeNewswire October 10, 2024

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

GlobeNewswire October 3, 2024

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire August 27, 2024

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 8, 2024

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

GlobeNewswire July 23, 2024

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 8, 2024

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

GlobeNewswire April 30, 2024

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

GlobeNewswire April 9, 2024

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 28, 2024

SCYNEXIS to Participate in Guggenheim's 6th Annual Biotechnology Conference

GlobeNewswire January 30, 2024

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

GlobeNewswire January 29, 2024

Scynexis Final Deadline Alert

Newsfile January 8, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX

Newsfile January 8, 2024

DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 8, 2024

Final Deadline Alert: Bronstein, Gewirtz & Grossman LLC Reminds Scynexis, Inc. (SCYX) Investors with Substantial Losses to Contact the Firm!

Accesswire January 8, 2024

SCYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Newsfile January 8, 2024

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Accesswire January 8, 2024

Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

PR Newswire January 8, 2024

SCYX DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important January 8 Deadline in Securities Class Action - SCYX

Newsfile January 7, 2024